Beyond the Scanner: QT Imaging Bets on AI with New Chief Science Officer

NOVATO, CA – July 29, 2026 – QT Imaging Holdings, Inc., a company known for its novel radiation-free breast imaging technology, has announced the appointment of Dr. Julia Albright as its new Chief Science Officer. While executive appointments are routine, this move is a clear signal of a much deeper strategic transformation underway at the Nasdaq-listed firm. The hiring of a seasoned executive with deep experience at Amazon Web Services, GE HealthCare, and Canon Medical Systems is less about filling a role and more about architecting a new future—one where the company evolves from a hardware manufacturer into a scalable, AI-driven precision health platform.

For years, QT Imaging has been developing its Breast Acoustic CT™ scanner, a system that uses low-frequency sound waves instead of radiation to create 3D images of the breast without the painful compression required by mammography. Now, with Dr. Albright at the scientific helm, the company is betting that the true value lies not just in the scanner itself, but in the vast quantities of data it generates and the intelligence that can be built upon it.

From Hardware to a Data-Driven Platform

The strategic pivot was articulated by CEO Dr. Raluca Dinu, who noted Dr. Albright’s background is “highly relevant as we evolve from a scanner company to a scalable precision imaging platform.” This statement encapsulates a fundamental shift occurring across the medical device industry: hardware is becoming the vehicle for a more lucrative and impactful data and software ecosystem. For QT Imaging, this means building out its QTI Cloud Platform, a system designed to manage imaging data and, eventually, deliver AI-powered analytics as a recurring-revenue service.

Dr. Albright’s resume makes her an ideal leader for this transition. Her most recent role was at Canon Medical Systems, but her previous tenures at Amazon Web Services and the quantitative imaging software firm CorTechs Labs are particularly telling. Her experience at AWS provides the critical cloud infrastructure expertise needed to build a robust, scalable digital health platform. This isn't just about storage; it's about creating an ecosystem for AI development, secure data sharing, and delivering software-as-a-service (SaaS) solutions to clinics and hospitals worldwide. This pivot is crucial for the company’s plan to generate recurring revenue beyond one-time scanner sales.

“QT Imaging has developed a truly differentiated imaging technology that combines a patient-centered experience with the ability to generate rich quantitative information,” Dr. Albright stated. Her focus on “unlock[ing] the full potential of QTI’s growing quantitative dataset” points directly to the company’s ambition to use artificial intelligence to extract new clinical insights, improve diagnostic accuracy, and ultimately personalize breast health management.

A New Front in Breast Imaging

QT Imaging is entering a crowded and well-established market dominated by mammography, the long-standing gold standard for breast cancer screening. While effective, mammography has known drawbacks: it uses ionizing radiation, requires uncomfortable breast compression, and can be less effective in women with dense breast tissue. These limitations have created an opening for new technologies that prioritize patient comfort and safety without sacrificing diagnostic quality.

The company’s acoustic CT technology is a direct response to this need. By providing a radiation-free and compression-free alternative, it offers a more patient-friendly experience that could improve screening compliance, particularly for younger women or those who require more frequent monitoring. This patient-centric approach is a key part of its unique selling proposition in a field where patient anxiety and discomfort are significant factors.

However, innovation alone doesn't guarantee market success. Adoption hinges on clinical validation and, crucially, reimbursement. Here, QT Imaging has made significant strides. The technology has received FDA 510(k) clearance, and the company recently secured a dedicated Category III CPT code, which will become effective in January 2027. This code is a critical milestone that paves the way for broader insurance coverage and simplifies billing for healthcare providers, removing a major barrier to clinical adoption.

The High-Stakes Path to Profitability

While the strategic vision is compelling, the road ahead for QT Imaging is a high-stakes journey typical of disruptive technology companies. The firm is in a rapid growth phase, with revenues projected to more than double to approximately $39 million in 2026. However, like many companies investing heavily in R&D and market expansion, it is not yet profitable, reporting a net loss of over $21 million in 2025. The company's stock has also seen significant volatility since its market debut, reflecting both the high potential and the inherent risks of its business.

The strategic shift towards an AI and cloud-based platform is therefore not just an innovation play; it is a core component of its path to profitability, which the company hopes to achieve by 2027. By adding a recurring SaaS revenue stream to its hardware sales, QT Imaging aims to build a more stable and scalable business model. Dr. Albright’s appointment is a calculated investment in the leadership required to execute this complex transition.

Her challenge will be to align the company’s scientific strategy, product roadmap, and clinical evidence generation to prove that this new model can deliver superior patient outcomes and financial returns. For QT Imaging, the future is not just about building a better scanner, but about building an intelligent system that redefines how we approach breast health. The success of this ambitious transformation will depend on the company's ability to seamlessly merge advanced hardware, sophisticated software, and clinical science into a cohesive and compelling platform.